HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

Volume: 3, Issue: 8, Pages: 1094 - 1101
Published: Aug 1, 2017
Abstract
Importance null Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. null Objective null To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity. null Design, Setting, and Participants null In this open-label phase 1 dose-escalation study conducted at Baylor College...
Paper Details
Title
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Published Date
Aug 1, 2017
Volume
3
Issue
8
Pages
1094 - 1101
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.